These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21377273)

  • 1. Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial.
    Rowbotham MC; Nothaft W; Duan RW; Wang Y; Faltynek C; McGaraughty S; Chu KL; Svensson P
    Pain; 2011 May; 152(5):1192-1200. PubMed ID: 21377273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of intradermal microdosing of a transient receptor potential cation channel subfamily V member 1 antagonist on heat evoked pain and thermal thresholds in normal and ultraviolet-C exposed skin in healthy volunteers.
    Sjögren E; Ståhle L; Quiding H; Jonzon B; Halldin MM; Sundgren AK
    Eur J Pain; 2019 Nov; 23(10):1767-1779. PubMed ID: 31314954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UV(B)-inflamed and normal skin.
    Schaffler K; Reeh P; Duan WR; Best AE; Othman AA; Faltynek CR; Locke C; Nothaft W
    Br J Clin Pharmacol; 2013 Feb; 75(2):404-14. PubMed ID: 22775239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the TRPV1 antagonist ABT-102 on body temperature in healthy volunteers: pharmacokinetic/ pharmacodynamic analysis of three phase 1 trials.
    Othman AA; Nothaft W; Awni WM; Dutta S
    Br J Clin Pharmacol; 2013 Apr; 75(4):1029-40. PubMed ID: 22966986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.
    Honore P; Chandran P; Hernandez G; Gauvin DM; Mikusa JP; Zhong C; Joshi SK; Ghilardi JR; Sevcik MA; Fryer RM; Segreti JA; Banfor PN; Marsh K; Neelands T; Bayburt E; Daanen JF; Gomtsyan A; Lee CH; Kort ME; Reilly RM; Surowy CS; Kym PR; Mantyh PW; Sullivan JP; Jarvis MF; Faltynek CR
    Pain; 2009 Mar; 142(1-2):27-35. PubMed ID: 19135797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo.
    Surowy CS; Neelands TR; Bianchi BR; McGaraughty S; El Kouhen R; Han P; Chu KL; McDonald HA; Vos M; Niforatos W; Bayburt EK; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
    J Pharmacol Exp Ther; 2008 Sep; 326(3):879-88. PubMed ID: 18515644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of the TRPV1 antagonist ABT-102 in healthy human volunteers: population analysis of data from 3 phase 1 trials.
    Othman AA; Nothaft W; Awni WM; Dutta S
    J Clin Pharmacol; 2012 Jul; 52(7):1028-41. PubMed ID: 21566201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, positive-controlled, 3-way cross-over human experimental pain study of a TRPV1 antagonist (V116517) in healthy volunteers and comparison with preclinical profile.
    Arendt-Nielsen L; Harris S; Whiteside GT; Hummel M; Knappenberger T; O'Keefe S; Kapil R; Kyle D
    Pain; 2016 Sep; 157(9):2057-2067. PubMed ID: 27168361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A first-in-human, double-blind, placebo-controlled, randomized, dose escalation study of DWP05195, a novel TRPV1 antagonist, in healthy volunteers.
    Lee J; Kim BH; Yu KS; Kim HS; Kim JD; Cho JY; Lee S; Gu N
    Drug Des Devel Ther; 2017; 11():1301-1313. PubMed ID: 28479852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans.
    Chizh BA; O'Donnell MB; Napolitano A; Wang J; Brooke AC; Aylott MC; Bullman JN; Gray EJ; Lai RY; Williams PM; Appleby JM
    Pain; 2007 Nov; 132(1-2):132-41. PubMed ID: 17659837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. γ-Aminobutyric acid (GABA) oral rinse reduces capsaicin-induced burning mouth pain sensation: An experimental quantitative sensory testing study in healthy subjects.
    Zhang Y; Wang K; Arendt-Nielsen L; Cairns BE
    Eur J Pain; 2018 Feb; 22(2):393-401. PubMed ID: 29024230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain.
    Krarup AL; Ny L; Gunnarsson J; Hvid-Jensen F; Zetterstrand S; Simrén M; Funch-Jensen P; Hansen MB; Drewes AM
    Scand J Gastroenterol; 2013 Mar; 48(3):274-84. PubMed ID: 23320520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of transient receptor potential vanilloid 1 (TRPV1) receptor antagonist compounds SB705498, BCTC and AMG9810 in rat models of thermal hyperalgesia measured with an increasing-temperature water bath.
    Tékus V; Bölcskei K; Kis-Varga A; Dézsi L; Szentirmay E; Visegrády A; Horváth C; Szolcsányi J; Petho G
    Eur J Pharmacol; 2010 Sep; 641(2-3):135-41. PubMed ID: 20534382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists.
    Cui M; Honore P; Zhong C; Gauvin D; Mikusa J; Hernandez G; Chandran P; Gomtsyan A; Brown B; Bayburt EK; Marsh K; Bianchi B; McDonald H; Niforatos W; Neelands TR; Moreland RB; Decker MW; Lee CH; Sullivan JP; Faltynek CR
    J Neurosci; 2006 Sep; 26(37):9385-93. PubMed ID: 16971522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, Pharmacokinetics, and Pharmacodynamics Study in Healthy Subjects of Oral NEO6860, a Modality Selective Transient Receptor Potential Vanilloid Subtype 1 Antagonist.
    Brown W; Leff RL; Griffin A; Hossack S; Aubray R; Walker P; Chiche DA
    J Pain; 2017 Jun; 18(6):726-738. PubMed ID: 28188907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management.
    Gomtsyan A; Bayburt EK; Schmidt RG; Surowy CS; Honore P; Marsh KC; Hannick SM; McDonald HA; Wetter JM; Sullivan JP; Jarvis MF; Faltynek CR; Lee CH
    J Med Chem; 2008 Feb; 51(3):392-5. PubMed ID: 18183945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain.
    Krarup AL; Ny L; Astrand M; Bajor A; Hvid-Jensen F; Hansen MB; Simrén M; Funch-Jensen P; Drewes AM
    Aliment Pharmacol Ther; 2011 May; 33(10):1113-22. PubMed ID: 21410733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of intravenous dexamethasone on the anaesthetic characteristics of peripheral nerve block: a double-blind, randomised controlled, dose-response volunteer study.
    Short A; El-Boghdadly K; Clarke H; Komaba T; Jin R; Chin KJ; Chan V
    Br J Anaesth; 2020 Jan; 124(1):92-100. PubMed ID: 31711605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multiple-dose double-blind randomized study to evaluate the safety, pharmacokinetics, pharmacodynamics and analgesic efficacy of the TRPV1 antagonist JNJ-39439335 (mavatrep).
    Manitpisitkul P; Flores CM; Moyer JA; Romano G; Shalayda K; Tatikola K; Hutchison JS; Mayorga AJ
    Scand J Pain; 2018 Apr; 18(2):151-164. PubMed ID: 29794306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized study to evaluate the analgesic efficacy of a single dose of the TRPV1 antagonist mavatrep in patients with osteoarthritis.
    Mayorga AJ; Flores CM; Trudeau JJ; Moyer JA; Shalayda K; Dale M; Frustaci ME; Katz N; Manitpisitkul P; Treister R; Ratcliffe S; Romano G
    Scand J Pain; 2017 Oct; 17():134-143. PubMed ID: 28850367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.